Management of early-stage ovarian cancer: Open questions and debated issues

IF 5.6 2区医学 Q1 HEMATOLOGY Critical reviews in oncology/hematology Pub Date : 2025-03-17 DOI:10.1016/j.critrevonc.2025.104704

V. Salutari , E. Giudice , E. Rapisarda , M. Pavone , V Ghizzoni , MT Perri , SM Boccia , S. Lardino , V. Gallotta , A. Fagotti , G. Scambia , D. Lorusso

{"title":"Management of early-stage ovarian cancer: Open questions and debated issues","authors":"V. Salutari , E. Giudice , E. Rapisarda , M. Pavone , V Ghizzoni , MT Perri , SM Boccia , S. Lardino , V. Gallotta , A. Fagotti , G. Scambia , D. Lorusso","doi":"10.1016/j.critrevonc.2025.104704","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>The management of epithelial ovarian cancer (EOC) is linked to the histological subtypes. However, literature did not provide strong evidence to support the best subtype-specific therapeutic strategy. In this review, we aim to summarizethe available evidenceto better guide the surgical and medical management of each specific EOC subtypes.</div></div><div><h3>Methods</h3><div>The article cited in this review were obtained quering the pubmed database in the English language between January 2007 and December 2024.</div></div><div><h3>Results</h3><div>Laparotomy remains the standard for surgical management of early-stage EOC. The roleof adjuvant chemotherapy remains an open issue due to outdated studies with small sample size.</div></div><div><h3>Conclusions</h3><div>Laparoscopy for the surgical management of early-staged EOC seems to be associated with equivalent oncologic outcome compared with laparotomy. The benefit of adjuvant chemotherapy is dependent on the histological subtype. Furthermore, targeted agents may replace adjuvant chemotherapy and clinical trials are urgently awaited.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"210 ","pages":"Article 104704"},"PeriodicalIF":5.6000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842825000927","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

The management of epithelial ovarian cancer (EOC) is linked to the histological subtypes. However, literature did not provide strong evidence to support the best subtype-specific therapeutic strategy. In this review, we aim to summarizethe available evidenceto better guide the surgical and medical management of each specific EOC subtypes.

Methods

The article cited in this review were obtained quering the pubmed database in the English language between January 2007 and December 2024.

Results

Laparotomy remains the standard for surgical management of early-stage EOC. The roleof adjuvant chemotherapy remains an open issue due to outdated studies with small sample size.

Conclusions

Laparoscopy for the surgical management of early-staged EOC seems to be associated with equivalent oncologic outcome compared with laparotomy. The benefit of adjuvant chemotherapy is dependent on the histological subtype. Furthermore, targeted agents may replace adjuvant chemotherapy and clinical trials are urgently awaited.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

早期卵巢癌的管理：开放的问题和争论的问题。

简介：上皮性卵巢癌（EOC）的治疗与组织学亚型有关。然而，文献并没有提供强有力的证据来支持最佳的亚型特异性治疗策略。在这篇综述中，我们旨在总结现有的证据，以更好地指导每个特定EOC亚型的手术和医疗管理。方法：检索pubmed数据库2007年1月至2024年12月的英文文献。结果：剖腹手术仍是早期EOC的标准手术治疗方法。由于过时的小样本量研究，辅助化疗的作用仍然是一个悬而未决的问题。结论：与剖腹手术相比，腹腔镜手术治疗早期EOC似乎具有相同的肿瘤预后。辅助化疗的益处取决于组织学亚型。此外，靶向药物可能取代辅助化疗，临床试验迫切等待。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Critical reviews in oncology/hematology 医学-血液学

CiteScore

11.00

自引率

3.20%

发文量

213

审稿时长

55 days

期刊介绍： Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.